ADORA2B
ENSG00000170425
Target class
GPCR
Chromosome
17
Approved drugs
8
Clinical candidates (approved and in development)
13
- Approved drugs
- 8
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Target name
- ADORA2B
- Gene name
- Adenosine A2b receptor
- Gene symbol
- ADORA2B
- Protein name
- Adenosine receptor A2b
- Gene biotype
- Protein coding
- Gene family
- Adenosine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 40
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 15.56
- Tissue specificity (Gini)
- 0.533
- Tissue specificity (tau)
- 0.773
- KEGG gene identifiers
- hsa:136
- Protein interaction confidence
- 0.82375
- Protein interaction partners
- 8
- R-HSA-417973
- R-HSA-418555
- R-HSA-5683826
- R-HSA-9660821
- End position
- 15975746
- Start position
- 15945130
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein.
- Plasma membrane
- Tissue specificity (tau)
- 0.773391
- Expression inequality (Gini)
- 0.532617
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)
- 15.56
- Esophagus - Mucosa
- 13.8
- Skin - Sun Exposed (Lower leg)
- 12.87
- Vagina
- 11.92
- Cells - Cultured fibroblasts
- 11.64
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)15.56
- Esophagus - Mucosa13.8
- Skin - Sun Exposed (Lower leg)12.87
- Vagina11.92
- Cells - Cultured fibroblasts11.64
- Brain - Anterior cingulate cortex (BA24)10.65
- Brain - Cortex9.93
- Colon - Transverse9.01
- Brain - Frontal Cortex (BA9)8.88
- Brain - Nucleus accumbens (basal ganglia)8.2
- Brain - Caudate (basal ganglia)6.61
- Brain - Cerebellum5.57
- Brain - Amygdala5.57
- Brain - Putamen (basal ganglia)5.45
- Brain - Hippocampus4.34
- Lung4.01
- Bladder3.99
- Pituitary3.85
- Brain - Cerebellar Hemisphere3.47
- Colon - Sigmoid3.39
- Testis3.06
- Brain - Hypothalamus2.96
- Prostate2.79
- Small Intestine - Terminal Ileum2.45
- Fallopian Tube2.16
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007190
Cellular components
- GO:0005886
Molecular functions
- GO:0005515
decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- immune
- peripheral nervous system
PubMed 28216264increased/decreased inflammation
- Activation/Increase/Upregulation: acute
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased/decreased inflammation
- immune
- peripheral nervous system
PubMed 28216264
Related records
Trials (753)
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
- 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
- A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
- A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
- A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
- A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
- A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
- A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
- A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
- A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Drugs (31)
- Adenosine Adenosine receptor agonist
- Aminophylline Adenosine receptor antagonist
- Binodenoson
- Caffeine Adenosine receptor antagonist
- Caffeine citrate Adenosine receptor antagonist
- Defibrotide Adenosine A2 receptor agonist
- Derenofylline
- Etrumadenant Adenosine A2b receptor antagonist
- FK453
- GS 6201 Adenosine A2b receptor antagonist
- GS-9667
- Imaradenant
- Istradefylline
- LAS101057 Adenosine A2b receptor antagonist
- LUF-5981
- Namodenoson
- Oxtriphylline Adenosine receptor antagonist
- Pentoxifylline Adenosine A2 receptor antagonist
- Piclidenoson
- Preladenant